文献速递中毒与环境急症重症综合管理与镇静镇痛

急诊科治疗甲基苯丙胺中毒:肌注氟哌利多、奥氮平、咪达唑仑与劳拉西泮的比较

Intramuscular droperidol, olanzapine, midazolam, or lorazepam to treat methamphetamine intoxication in the emergency department.
PubMed 文献 · Am J Emerg Med · 2026-02-17
一句话结论急诊科肌注氟哌利多、奥氮平或咪达唑仑治疗甲基苯丙胺相关激越的起效速度和有效性与肌注劳拉西泮相比更快更有效。

该研究为2019至2020年既往数据的二次分析,纳入122例急诊科甲基苯丙胺相关激越患者,比较肌注氟哌利多、奥氮平、咪达唑仑和劳拉西泮的效果。主要终点为达到充分镇静的时间(TAS,AMSS≤0)。氟哌利多(中位5 mg)TAS 16分钟、奥氮平(中位10 mg)16分钟、咪达唑仑(中位5 mg)13分钟、劳拉西泮(中位2 mg)29分钟;劳拉西泮与更长的TAS相关(p<0.001)。15分钟充分镇静比例:氟哌利多43%、奥氮平45%、咪达唑仑60%、劳拉西泮32%;需补救用药比例:氟哌利多16%、奥氮平20%、咪达唑仑13%、劳拉西泮46%。不良事件无差异。

要点

  • 肌注氟哌利多中位5 mg、奥氮平中位10 mg、咪达唑仑中位5 mg治疗甲基苯丙胺相关激越的TAS分别为16、16、13分钟,三者效果相似。
  • 肌注劳拉西泮中位2 mg的TAS为29分钟,比例风险分析显示劳拉西泮与更长的TAS相关(p<0.001)。
  • 15分钟充分镇静(AMSS≤0)比例:咪达唑仑60%、奥氮平45%、氟哌利多43%、劳拉西泮32%。
  • 需补救用药比例:咪达唑仑13%、氟哌利多16%、奥氮平20%、劳拉西泮46%。
  • 四组不良事件无差异。

适用人群与场景

  • 急诊科就诊的急性甲基苯丙胺相关激越患者,需接受肌注药物治疗者。

诊断标准与关键阈值

  • 采用精神状态改变量表(AMSS)评估,充分镇静定义为AMSS≤0。

处置流程与药物剂量

  • 肌注氟哌利多中位剂量5 mg。
  • 肌注奥氮平中位剂量10 mg。
  • 肌注咪达唑仑中位剂量5 mg。
  • 肌注劳拉西泮中位剂量2 mg。

研究设计与关键结果

  • 研究类型:2019至2020年既往已发表数据的二次分析;样本量122例;药物、剂量、给药途径和激越病因由治疗医师决定。
  • 主要终点TAS:氟哌利多(37例,中位5 mg)16分钟,奥氮平(44例,中位10 mg)16分钟,咪达唑仑(15例,中位5 mg)13分钟,劳拉西泮(26例,中位2 mg)29分钟;比例风险分析显示劳拉西泮与更长的TAS相关(p<0.001)。
  • 15分钟充分镇静比例:氟哌利多43%,奥氮平45%,咪达唑仑60%,劳拉西泮32%。
  • 补救用药比例:氟哌利多16%,奥氮平20%,咪达唑仑13%,劳拉西泮46%。
  • 不良事件:四组间无差异。

证据类型、等级与局限

  • 证据类型:二次分析(基于2019至2020年既往已发表数据)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急诊科甲基苯丙胺相关激越需肌注药物的患者,肌注氟哌利多、奥氮平或咪达唑仑均比肌注劳拉西泮起效更快、15分钟充分镇静比例更高、补救用药更少。
  • 肌注劳拉西泮与更长的TAS相关(p<0.001),15分钟充分镇静比例最低(32%),补救用药比例最高(46%)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Emergency department (ED) visits for acute methamphetamine-associated agitation are increasing. Many cases require parenteral medications. Benzodiazepines are often recommended first-line, however randomized trials of intravenous medications suggest antipsychotics are also effective. High-quality data on intramuscular medications are lacking.

OBJECTIVE: To compare the effectiveness of intramuscular droperidol, olanzapine, midazolam, and lorazepam to treat methamphetamine-associated agitation in the ED.

METHODS: This was a secondary analysis of previously published data from 2019 to 2020; medication, dose, route, and agitation etiology were determined by treating physicians. The primary outcome was time to adequate sedation (TAS), assessed via the Altered Mental Status Scale (AMSS), defined as time to AMSS≤0. Secondary outcomes included use of additional (rescue) medications and adverse events.

RESULTS: We analyzed 122 patients with similar baseline characteristics; 37 received droperidol (median dose 5 mg, TAS 16 min), 44 received olanzapine (median dose 10 mg, TAS 16 min), 15 received midazolam (median dose 5 mg, TAS 13 min), and 26 received lorazepam (median dose 2 mg, TAS 29 min). Proportional hazards analysis showed lorazepam was associated with longer TAS (p < 0.001). The proportion of patients adequately sedated at 15 min was 43% for droperidol, 45% for olanzapine, 60% for midazolam, and 32% for lorazepam. The proportion of patients receiving rescue medication was 16% for droperidol, 20% for olanzapine, 13% for midazolam, and 46% for lorazepam. We found no difference in adverse events.

CONCLUSIONS: Intramuscular droperidol, olanzapine, and midazolam were all similarly effective for treating methamphetamine-associated agitation. All three medications provided more rapid and effective sedation than intramuscular lorazepam.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Cole JB, DeVries PA, O'Flaherty JL, et al. Intramuscular droperidol, olanzapine, midazolam, or lorazepam to treat methamphetamine intoxication in the emergency department. Am J Emerg Med. 2026. PMID: 41740194. doi:10.1016/j.ajem.2026.02.027

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。